Role of Clinical Laboratories in Early Detection of Sepsis
DOI:
https://doi.org/10.22399/ijcesen.4643Keywords:
Clinical laboratories, early detection, sepsis, diagnostics, blood cultures, complete blood count, C-reactive proteinAbstract
Clinical laboratories play a pivotal role in the early detection of sepsis, a life-threatening condition caused by the body’s response to infection. Quick and accurate laboratory diagnostics are essential for identifying the pathogens responsible for sepsis, as well as for assessing the host's response to infection. Common laboratory tests, including complete blood counts (CBC), blood cultures, and biochemical markers like C-reactive protein (CRP) and procalcitonin, help clinicians recognize the early signs of sepsis. The rapid turnaround time for these tests is critical, as early diagnosis and treatment significantly reduce morbidity and mortality associated with sepsis. By leveraging advanced techniques such as multiplex polymerase chain reaction (PCR) and next-generation sequencing, clinical laboratories can swiftly identify infectious agents and guide targeted therapy. Moreover, clinical laboratories are integral to the continuous monitoring of patients suspected of having sepsis. Ongoing assessments through repeated laboratory testing can provide invaluable insights into a patient’s evolving condition and response to treatment. For instance, trends in laboratory markers can indicate whether a patient is improving or deteriorating, prompting timely adjustments to their management plan. The integration of laboratory data with clinical assessments enables healthcare teams to make informed decisions, improving sepsis outcomes. Overall, the collaboration between clinical laboratories and healthcare providers is critical in the fight against sepsis, emphasizing the importance of laboratory capabilities in enhancing patient care.
References
1. Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R, et al. Surviving sepsis campaign: Association between performance metrics and outcomes in a 7.5-year study. Critical Care Medicine. 2015;43:3–12.
2. Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin used as a marker of infection in the intensive care unit. Critical Care Medicine. 1999;27:498–504.
3. Debiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang Y, et al. The utility of proadrenomedullin and procalcitonin in comparison to c-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Critical Care Medicine. 2014;42:2500–2507.
4. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123:2043–2049.
5. Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. American Journal of Respiratory and Critical Care Medicine. 2016;193:259–272.
6. Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: Value of c-reactive protein compared with other clinical and biological variables. Critical Care Medicine. 2002;30:529–535.
7. Mikkelsen ME, Miltiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Critical Care Medicine. 2009;37:1670–1677.
8. Calfee CS, Thompson BT, Parsons PE, Ware LB, Matthay MA, Wong HR. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Critical Care Medicine. 2010;38:1436–1441.
9. Dugas AF, Mackenhauer J, Salciccioli JD, Cocchi MN, Gautam S, Donnino MW. Prevalence and characteristics of nonlactate and lactate expressors in septic shock. Journal of Critical Care. 2012;27:344–350.
10. Tettamanti C, Hervet T, Grabherr S, Palmiere C. Elevation of nt-probnp and cardiac troponins in sepsis-related deaths: A forensic perspective. International Journal of Legal Medicine. 2016.
11. Shapiro NI, Trzeciak S, Hollander JE, Birkhahn R, Otero R, Osborn TM, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Critical Care Medicine. 2009;37:96–104.
12. Schmit X, Vincent JL. The time course of blood c-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection. 2008;36:213–219.
13. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clinical Chemistry. 2004;50:1301–1314.
14. Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N, et al. Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: A prospective, observational, cohort study. Journal of Critical Care. 2015;30:218.e7–12.
15. Kelly BJ, Lautenbach E, Nachamkin I, Coffin SE, Gerber JS, Fuchs BD, et al. Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis. Diagnostic Microbiology and Infectious Disease. 2016;85:109–115.
16. Du B, Pan J, Chen D, Li Y. Serum procalcitonin and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious and non-infectious origin. Chinese Medical Journal. 2003;116:538–542.
17. O’Callaghan DJ, O’Dea KP, Scott AJ, Takata M, Gordon AC. Monocyte tumor necrosis factor-alpha-converting enzyme catalytic activity and substrate shedding in sepsis and noninfectious systemic inflammation. Critical Care Medicine. 2015;43:1375–1385.
18. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, Weiss JW. Serum lactate as a predictor of mortality in emergency department patients with infection. Annals of Emergency Medicine. 2005;45:524–528.
19. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Critical Care Medicine. 2011;39:2048–2058.
20. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein as a marker of infection in critically ill patients. Clinical Microbiology and Infection. 2005;11:101–108.
21. USA B. Press release fda approved pct for sepsis.
22. Castelli GP, Pognani C, Cita M, Stuani A, Sgarbi L, Paladini R. Procalcitonin, c-reactive protein, white blood cells and sofa score in icu: Diagnosis and monitoring of sepsis. Minerva Anestesiologica. 2006;72:69–80.
23. Sridharan P, Chamberlain RS. The efficacy of procalcitonin as a biomarker in the management of sepsis: Slaying dragons or tilting at windmills? Surgical Infections. 2013;14:489–511.
24. Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype? Swiss Medical Weekly. 2015;145:w14079.
25. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA. 2016;315:801–810.
26. Zhang Z, Ni H. C-reactive protein as a predictor of mortality in critically ill patients: A meta-analysis and systematic review. Anaesthesia and Intensive Care. 2011;39:854–861.
27. Cheng H, Fan WZ, Wang SC, Liu ZH, Zang HL, Wang LZ, et al. N-terminal pro-brain natriuretic peptide and cardiac troponin i for the prognostic utility in elderly patients with severe sepsis or septic shock in intensive care unit: A retrospective study. Journal of Critical Care. 2015;30:654.e9–14.
28. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. Early identification of intensive care unit-acquired infections with daily monitoring of c-reactive protein: A prospective observational study. Critical Care. 2006;10:R63.
29. Howell MD, Donnino M, Clardy P, Talmor D, Shapiro NI. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Medicine. 2007;33:1892–1899.
30. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science. 2015;347:1260–1265.
31. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (copd): A qualitative clinical review. Clinical Chemistry and Laboratory Medicine. 2015;53:521–539.
32. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the genetic and inflammatory markers of sepsis (genims) study. Archives of Internal Medicine. 2007;167:1655–1663.
33. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine. 2013;41:580–637.
34. Grolimund E, Kutz A, Marlowe RJ, Vogeli A, Alan M, Christ-Crain M, et al. Long-term prognosis in copd exacerbation: Role of biomarkers, clinical variables and exacerbation type. COPD. 2014.
35. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The accp/sccm consensus conference committee. American college of chest physicians/society of critical care medicine. Chest. 1992;101:1644–1655.
36. Junhasavasdikul D, Theerawit P, Ingsathit A, Kiatboonsri S. Lactate and combined parameters for triaging sepsis patients into intensive care facilities. Journal of Critical Care. 2016;33:71–77.
37. Yao L, Liu Z, Zhu J, Li B, Chai C, Tian Y. Higher serum level of myoglobin could predict more severity and poor outcome for patients with sepsis. American Journal of Emergency Medicine. 2016.
38. Wenzel RP, Edmond MB. Managing antibiotic resistance. New England Journal of Medicine. 2000;343:1961–1963.
39. Shin TG, Jo IJ, Hwang SY, Jeon K, Suh GY, Choe E, et al. Comprehensive interpretation of central venous oxygen saturation and blood lactate levels during resuscitation of patients with severe sepsis and septic shock in the emergency department. Shock. 2016;45:4–9.
40. Faix JD. Biomarkers of sepsis. Critical Reviews in Clinical Laboratory Sciences. 2013;50:23–36.
41. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006;34:1589–1596.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
